Bristol-Myers Squibb Company (BMY) fair value analysis
S&P 500 · Updated 2026-10-19
BMY price how computed
Forward Fair Value verdict
OvervaluedBMY is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $59.12
- Sector
- Healthcare
- 12-month range
- $42.60–$68.09
- Market cap
- $121B
- From 52-week high
- -13.2%
- Shares outstanding
- 2.04B
- Rank in Healthcare by discount to fair value
- #72 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines for treating diseases including cancer, cardiovascular disease, immunology conditions, and cell therapy. The company operates research, development, and manufacturing facilities across multiple countries worldwide and sells its products to healthcare systems and patients internationally.
BMY currently ranks #72 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $121B
- P/E (trailing)
- 9x
- Revenue (TTM)
- $49.2B
- Net margin
- 18.9%
- EPS (TTM)
- $6.51
- Gross margin
- 71.3%
- Debt / equity
- 1.93
- Revenue growth (3-yr avg)
- 6.1%
- Shares outstanding
- 2.04B
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 46 · neutral
- 50-day average
- $63.51
- 200-day average
- $59.64
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.52 per share (4 payments)
- Yield on last price
- 4.26%
- Consecutive years of increases
- 4
- Last ex-dividend date
- 2026-10-02
- Last payment date
- 2026-11-02
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+28.3%)
2026-03 ▲ beat (+11.3%)
2025-12 ▲ beat (+5.0%)
2025-09 ▲ beat (+7.2%)
2025-06 ▲ beat (+32.7%)
2025-03 ▲ beat (+20.0%)
2024-12 ▲ beat (+13.6%)
2024-09 ▲ beat (+20.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 17 hold · 1 sell (28 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $65.6
- Target vs last price
- +11.0%
What our data shows for BMY
- Our model validated 17 trailing price-to-earnings windows for BMY, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $42.60–$68.09.
- The 14-day relative strength index sits at a neutral 46.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BMY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BMY news
TickrTrends' derived news-sentiment signal for BMY is currently mixed, computed from recent coverage.
- Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings (NYSE:BMY) (seekingalpha.com, 2026-10-21)
TickrTrends take: Bristol-Myers Squibb trades at an overvalued level according to TickrTrends metrics despite positive sentiment ahead of its Q3 earnings report. A valuation-focused investor should monitor whether the company's earnings results and forward guidance justify the current price premium, particularly given the Healthcare sector's competitive dynamics. The gap between bullish sentiment and stretched valuation suggests that execution and revenue growth will be critical factors in determining whether the stock can sustain its current levels. - Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff? (insidermonkey.com, 2026-10-20)
TickrTrends take: Bristol Myers operates in the Healthcare sector where patent expirations can create significant revenue headwinds. TickrTrends currently rates BMY as overvalued, which suggests the market may already be pricing in optimistic assumptions about the company's ability to offset upcoming patent losses through new cancer therapeutics. Investors focused on valuation metrics should monitor whether the company's pipeline developments can materially reverse the revenue trajectory once key patents expire, as this will determine whether current pricing reflects realistic growth prospects. - Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity? (insidermonkey.com, 2026-10-20)
TickrTrends take: Bristol Myers Squibb trades at a significant valuation discount relative to peer Eli Lilly, which TickrTrends currently assesses as overvalued based on derived metrics. A valuation-focused reader should monitor whether BMY's discount reflects genuine fundamental weakness in its Healthcare sector operations or represents a temporary market mispricing that could narrow over time. The relative positioning of both companies' valuations suggests watching for developments in pipeline progress, revenue growth, and profitability trends that could justify or further compress the valuation gap between them.
More BMY news
- Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside? (insidermonkey.com, 2026-10-16)
- Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It (zacks.com, 2026-10-14)
- Bristol Myers (BMY) Advances IPF Treatment with Admilparant Phase III Success (gurufocus.com, 2026-10-12)
- Bristol Myers (BMY) Reports Promising Phase 3 Trial Results for Admilparant in IPF (gurufocus.com, 2026-10-12)
- Bristol Myers (BMY) Addresses Adamilparant Trial Fatality as Shares Dip 4% (gurufocus.com, 2026-10-12)
What people are saying
Follow the BMY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BMY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BMY is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is BMY's TickrTrends verdict?
BMY's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does BMY compare to other Healthcare stocks?
BMY ranks #72 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BMY overbought or oversold?
BMY's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does BMY pay a dividend?
Yes. BMY paid $2.52 per share over the last twelve months (4 payments), a 4.26% yield on TickrTrends' last price, and has raised the annual total for 4 consecutive years. The last ex-dividend date was 2026-10-02.
When does BMY report earnings next?
BMY's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does BMY usually beat earnings estimates?
Over its last 8 reported quarters BMY beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BMY?
Of 28 analysts covering BMY, 10 rate it a buy, 17 a hold and 1 a sell - hold-leaning, with a consensus price target of $65.6 (+11.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BMY vs ACAD · BMY vs BIIB · BMY vs BLLN · BMY vs BVS · BMY vs CAH